Therapeutic radiopharmaceuticals are used for the treatment of primary cancer, metastasis or for palliation of bone pain associated with metastastic bone cancer. In order to widen the application of targeted therapy, there is a need for the standardization of easy and economically viable production methods for promising therapeutic radioisotopes with the existing nuclear reactors available in the MS. 177Lu is a radioisotope having very good potential for use in in-vivo therapy, because of its favourable decay characteristics. The overall objective of the CRP is to generate know how and expertise in participating laboratories on the production 177Lu and development of 177Lu-based radiopharmaceuticals of high purity and stability for preclinical and clinical investigation as potential therapeutic agents in particular as bone pain palliation agents, with a focus on 177Lu -Phosphonates.